SRR8518220
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_GAMMA_RESPONSE+0.500
- ALLOGRAFT_REJECTION+0.480
- INTERFERON_ALPHA_RESPONSE+0.450
- IL6_JAK_STAT3_SIGNALING+0.420
- INFLAMMATORY_RESPONSE+0.370
- KRAS_SIGNALING_UP+0.330
- TNFA_SIGNALING_VIA_NFKB+0.300
- IL2_STAT5_SIGNALING+0.240
- COMPLEMENT+0.210
- PANCREAS_BETA_CELLS+0.070
Top 10 suppressed
- MYC_TARGETS_V2-0.520
- CHOLESTEROL_HOMEOSTASIS-0.440
- ESTROGEN_RESPONSE_EARLY-0.430
- ESTROGEN_RESPONSE_LATE-0.420
- MYC_TARGETS_V1-0.420
- OXIDATIVE_PHOSPHORYLATION-0.420
- GLYCOLYSIS-0.410
- E2F_TARGETS-0.380
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.380
- ADIPOGENESIS-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | be8d8236-4ebc-46de-a4fd-a901fec1cdce | — | — | 0.930 |
| 2 | ERR4976618 | — | D | 0.909 |
| 3 | SRR1313132 | — | D | 0.885 |
| 4 | SRR10900583 | — | — | 0.882 |
| 5 | SRR8942978 | — | — | 0.879 |
| 6 | 3c5fe4dc-8606-4615-994f-c41861f08f5a | — | — | 0.878 |
| 7 | 6b907244-c173-4e29-a163-24258a430477 | — | — | 0.874 |
| 8 | SRR2932841 | — | — | 0.872 |
| 9 | BS_J6VKB1VE | low-grade glioma | — | 0.869 |
| 10 | SRR8518255 | — | D | 0.869 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_GAMMA_RESPONSE | 0.500 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.480 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.450 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.420 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.370 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.330 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.300 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.240 | Idelalisib | — uncovered |
| COMPLEMENT | 0.210 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.070 | Cobimetinib | — uncovered |
| PROTEIN_SECRETION | 0.040 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.040 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.010 | Temsirolimus | — uncovered |